Skip to search formSkip to main content

c-Met Inhibitor MSC2156119J

Known as: MSC2156119J 
An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic… Expand
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstract 4663: Combination of c-Met inhibitor tepotinib (MSC2156119J) and a third-generation EGFR inhibitor can overcome double resistance mediated by EGFR T790M mutation and c-Met amplification in…
In clinical practice, acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer… Expand
Is this relevant?
2015
2015
Efficacy, safety, biomarkers, and phase II dose modeling in a phase I trial of the oral selective c-Met inhibitor tepotinib (MSC2156119J).
2591 Background: Tumor c-Met overexpression is associated with tumor aggression and poor prognosis, making it a target for… Expand
Is this relevant?
2015
2015
Abstract 4510: Model-based phase II dose selection of c-Met inhibitor MSC2156119J
Objectives: To evaluate the dose/exposure/target inhibition/tumor growth relationship of MSC2156119J, an orally administered… Expand
Is this relevant?
2015
2015
2353 Data from a phase Ib/II trial of the oral c-Met inhibitor tepotinib (MSC2156119J) as first-line therapy in Asian patients with advanced hepatocellular carcinoma
s S453 tepotinib (MSC2156119J) demonstrated promising antitumor activity in a phase I trial. Pharmacokinetic/pharmacodynamic… Expand
  • table 1
Is this relevant?
2014
2014
The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models
The mesenchymal-epithelial transition factor (c-Met) is a receptor tyrosine kinase with hepatocyte growth factor (HGF) as its… Expand
  • figure 3
  • table 1
Is this relevant?
2014
2014
Results of the first-in-human phase I trial assessing MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients (pts) with advanced solid tumors.
2521^ Background: MSC2156119J, a selective c-Met inhibitor, suppresses tumor growth in preclinical models. Methods: Primary… Expand
Is this relevant?
2014
2014
A multicenter, randomized, phase Ib/II trial of the oral c-Met inhibitor MSC2156119J as monotherapy versus sorafenib in Asian patients with MET-positive (MET+) advanced hepatocellular carcinoma (HCC…
TPS4151 Background: Patients (pts) with HCC have a poor prognosis. Effective treatments are limited, particularly in Asia, which… Expand
Is this relevant?
2014
2014
Abstract CT236: MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients with advanced solid tumors: results of the first-in-human phase I trial
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Introduction: Overexpression of the c-Met oncoprotein can… Expand
Is this relevant?
2014
2014
Phase I/II multicenter, randomized, open-label trial of the c-Met inhibitor MSC2156119J and gefitinib versus chemotherapy as second-line treatment in patients with MET-positive (MET+), locally…
TPS8121 Background: Resistance to EGFR tyrosine kinase inhibitors (eg, gefitinib) in EGFRm+ NSCLC patients (pts) is mainly caused… Expand
Is this relevant?
2013
2013
Abstract 925: The c-Met inhibitor MSC2156119J effectively inhibits growth of liver cancer models.
The mesenchymal-epithelial transition factor (c-Met) receptor, also known as hepatocyte growth factor receptor (HGFR), controls… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE